Aspira Women's Health Inc. · OTC:AWHL

Aspira Women's Health — Investor Presentation (June 2022)

19 slides from Aspira Women's Health's investor presentation, Jun 7, 2022

  1. Slide 1: Transforming the State of Women's Gynecological Health... Starting with Ovarian Cancer

    Slide 1: Transforming the State of Women's Gynecological Health... Starting with Ovarian Cancer

    Transforming the State of Women’s Gynecological Health... Starting with Ovarian Cancer Corporate Presentation | June 2022 Nicole Sandford, President and CEO Bob Beechey, Chief Financial Officer

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements include, am

  3. Slide 3: Investment Highlights

    Slide 3: Investment Highlights

    Investment Highlights Commercial : : : Revenue-generating test for multi-modal ovarian cancer risk assessment FDA-cleared Technologies ar Focused fiaeustiasli i i i Compelling pipeline of gynecological diagnostic tools Intellectual i Strong IP and technology protection Managed Care Approximately 200

  4. Slide 4: Recent Developments

    Slide 4: Recent Developments

    Recent Developments Aspira will collaborate with BioReference Laboratories, Inc., an OPKO Health company and the largest full-service specialty laboratory in the United States, to offer OVA1Plus, which includes Aspira’s FDA-cleared Ova1 and Overa ovarian cancer risk assessments. BioReference + With

  5. Slide 5: Starting with Ovarian Cancer...

    Slide 5: Starting with Ovarian Cancer...

    Starting with Ovarian Cancer... Most Ovarian Cancer Detected at Late Stage — When It’s Most Deadly Presentation Stage | Stage Il Stage Ill Stage IV Stage Local Pelvic Regional nodes Distant spread Incidence a “ pm Five Year 2% % 29% 24% Survival Rate? ° e ° Ovarian Cancer Diagnosed in the Late Stage

  6. Slide 6: Current Standard of Care for Assessing Cancer Treatment

    Slide 6: Current Standard of Care for Assessing Cancer Treatment

    Current Standard of Care for Assessing Cancer Treatment Clinical Assessment Physical exam and ultrasound CA 125 (off-label) ROMA™ (alternative) Limitations: Subjective results and Limitations: Low sensitivity and reliance on physician high false negatives, especially in and technician experience pre

  7. Slide 7: A Better Blood Risk Assessment

    Slide 7: A Better Blood Risk Assessment

    A Better Blood Risk Assessment Cva J OVA products demonstrate better performance in early-stage risk detection OVA risk assessment products 31% substantially improve the effectiveness of clinical assessment in stratifying the risk of Stage 1 and Stage 2 malignancy for women with pelvic masses planne

  8. Slide 8: Significant Market Opportunity

    Slide 8: Significant Market Opportunity

    Significant Market Opportunity OVA products address the unmet need and represent a significant growth opportunity for Aspira. OVA1Plus Pelvic Mass — Potential Revenue Women Planned For Surgery $100M-140M TAM=300-400K OVAWatch Pelvic Mass (one time and serial mass monitoring) TAM=1.2-1.5M Potential R

  9. Slide 9: Commercial Strategy

    Slide 9: Commercial Strategy

    Commercial Strategy The expansion and commercialization of our OVA products is a top priority for 2022 Commercial Strategy Focus Sales Force Optimization Targeting gynecologic specialists, Adoption and Coverage 26 full-time women’s health specialized sales groups and professionals healthcare systems

  10. Slide 10: Adoption and Coverage

    Slide 10: Adoption and Coverage

    Adoption and Coverage OVA Adoption Since Introduction of Second-Generation Test OVA volumes have increased o' time even during the Covid pandemic Professional Society Suppo: 5000 _ #ACOG © £ 2 4000 $ 8 © 3500 Boley 6F Gypeolgic Oncaigs $ fe} 3000 SpecialtyHealth, 2500 BORG evicore * 2000 healtheare’

  11. Slide 11: OVA Adoption by Physicians Continues to Improve

    Slide 11: OVA Adoption by Physicians Continues to Improve

    OVA Adoption by Physicians Continues to Improve Total Ordering Physicians 3500 3000 66 OVAtplus™ has made a big difference in my practice because it has added more aop8 certainty to decision-making and given us more confidence in treating patients. 99 2090! ObGyn 66 | ask my referring OBGYN’s 1500 a

  12. Slide 12: Market Access

    Slide 12: Market Access

    Market Access Our goal is to make OVA products available to all women 168 Million Commercial lives covered HCSC {Cigna a ® A&E <HIIGHMARK. —WAwellCare TRICARE eth Pans Commercial coverage also includes Medicare Advantage plans sponsored by additional commercial payers 66% of all commercial lives cov

  13. Slide 13: OVAWatch

    Slide 13: OVAWatch

    CvawatTcH OVAWatch is our third generation OVA product. It is a non-invasive Lab Developed Test (LDT) to be used in conjunction with clinical assessment to determine the risk of ovarian cancer for patients with an adnexal mass. « Expands patient population from OVA1Plus which is FDA Launch in two st

  14. Slide 14: OVAWatch Launch Plan

    Slide 14: OVAWatch Launch Plan

    CvawaT,cH Launch Plan Product Expansion Initial Commercial Launch 2H 2022 Targeted for second half 2022; revenue in 2023 Pricing/Reimbursement In process Cross-walk from existing reimbursement arrangements for OVA1Plus Clinical Validation In process Analysis of interim data from prospective real-wor

  15. Slide 15: Endometriosis is an Unmet Need — and Market Opportunity

    Slide 15: Endometriosis is an Unmet Need — and Market Opportunity

    |e | Endometriosis is an Unmet Need — and Market Opportunity Product Expansion Health Cost 6-7 mition women affected in the Burden tener For women diagnosed with Endometriosis in the U.S. is similar to * EndoCheck™ is our in-development Average to diagnose test for endometriosis targeted for the cos

  16. Slide 16: Aspira Synergy: Phases of the Client Relationship Lifecycle

    Slide 16: Aspira Synergy: Phases of the Client Relationship Lifecycle

    Aspira Synergy: Phases of the Client Relationship Lifecycle Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Agreement Implementation Launch Adoption/Scale Optimization Super Group A s Salesand Adoption: = guneent + Revenue Drive awareness and Regional physician adoption LabB Regional o LabA = Client Validat

  17. Slide 17: Financial Performance Snapshot

    Slide 17: Financial Performance Snapshot

    Financial Performance Snapshot Qi vs. Last Year OVA Product Volume INCREASED 28% 4,819 units in O2FY22 vs. 3,775 units in Q1FY21 OVA Product Revenue INCREASED 29% $1.8M in Q1FY22 vs. $1.4M in Q1FY22 Profitability GM 53.2% Total Customers INCREASED 26% 3,275 physicians in Q1FY22 vs. 2,595 physicians

  18. Slide 18: In Conclusion ...

    Slide 18: In Conclusion ...

    In Conclusion ... Our strategy is sound, the path forward is clear. 2022 is about Accelerated Development Ova?” CvawaTcH End ocHECK Operational Excellence ¥ 18 Adoption and Volume Initial Launch

  19. Slide 19: Contact Information

    Slide 19: Contact Information

    Contact Information Ashley R. Robinson LifeSci Advisors, LLC [email protected]

Source: SEC EDGAR · 8-K filed Jun 7, 2022

More decks from Aspira Women's Health Inc.

All 21 Aspira Women's Health decks